– Bloomberg
Abbisko, Lilly Ink Licensing Pact For Cardiometabolic Diseases
Abbisko Therapeutics has entered into a worldwide collaboration and exclusive licensing agreement with Eli Lilly And Co (NYSE: LLY) for novel molecules against an
Related Posts
Stifel Maintains Buy on Carvana, Lowers Price Target to $170
Stifel analyst Scott Devitt maintains Carvana (NYSE:CVNA) with a Buy and lowers the price target from $180 to $170.
Eyenovia Has Filed For FCC ID Approval On EYENOVIAGEN1 Optejet Base G1.
https://fccid.io/2A2VJ-EYENOVIAGEN1
NetEase’s Cloud Music Prosecutes Tencent Music
NetEase, Inc's (NASDAQ: NTES) Cloud Music unit prosecuted Tencent Music Entertainment Group (NYSE: TME) for alleged unfair competition and plagiarizing its app design, Reuters reports.